Recipharm Competitors and Similar CompaniesClear all

Recipharm's competitors and similar companies include Bausch Health Americas, Akums Drugs and Pharmaceuticals, Hypera Pharma and Innovent Biologics.

	Recipharm Recipharm is a pharmaceutical contract development and manufacturing company.	Bausch Health Americas Bausch Health Americas (BHA) is a pharmaceutical preparation manufacturing company.	Akums Drugs and Pharmaceuticals Akums Drugs and Pharmaceuticals is a contract development and manufacturing organization (CDMO).	Hypera Pharma Hypera Pharma is a pharmaceutical company that provides medicines and food supplements.	Innovent Biologics Innovent Biologics is a biopharmaceutical company that develops and manufactures drugs.
Founding Date	Founding Date 1995	Founding Date 1994	Founding Date 2004	Founding Date 2001	Founding Date 2011
Type	Type Private	Type Subsidiary	Type Private	Type Public	Type Public
Tags	Tags Manufacturing & Industrial drug development pharma	Tags Manufacturing & Industrial drug development pharma	Tags Healthcare drug development pharma	Tags Manufacturing & Industrial drug development pharma	Tags Manufacturing & Industrial drug development pharma
Locations	Locations Stockholm, SE HQ Kaysersberg, FR Cuxhaven, DE Monheim Am Rhein, DE Wasserburg Am Inn, DE Zwickau, DE Bengaluru, IN see more	Locations Bridgewater, US HQ Laval, CA Steinbach, CA Envigado, CO La Estrella, CO Medellín, CO Ciudad De México, MX see more	Locations Delhi, IN HQ Delhi, IN	Locations São Paulo, BR HQ	Locations Suzhou, CN HQ
Employees	Employees 7,40915% decrease	Employees 4,044	Employees 4,4829% increase	Employees 10,481	Employees 5,659
Financial
Revenue (est.)	Revenue (est.) kr705.5m (FY, 2023)	Revenue (est.) N/A	Revenue (est.) N/A	Revenue (est.) R$7.7b (FY, 2025)	Revenue (est.) ¥13b (FY, 2025)
Cost of goods	Cost of goods N/A	Cost of goods N/A	Cost of goods N/A	Cost of goods R$2.8b (FY, 2025)	Cost of goods ¥1.1b (FY, 2025)
Gross profit	Gross profit N/A	Gross profit N/A	Gross profit N/A	Gross profit R$4.9b (FY, 2025)	Gross profit ¥12b (FY, 2025)
Net income	Net income (kr8.8b) (FY, 2023)	Net income N/A	Net income N/A	Net income R$1.2b (FY, 2025)	Net income ¥813.6m (FY, 2025)
Funding
Latest funding round	Latest funding round $ 32m (over 10 years ago)	Latest funding round N/A	Latest funding round $ 70m (over 6 years ago)	Latest funding round N/A	Latest funding round N/A
Total funding raised	Total funding raised $ 242.4m	Total funding raised N/A	Total funding raised $ 70m	Total funding raised N/A	Total funding raised N/A